CONFERENCE PROGRAM

Sunday, October 1

4:00 p.m.-6:00 p.m.  EDUCATIONAL SESSION
Ballroom 1
Please refer to Program and Proceedings supplement for more information.

6:15 p.m.-7:30 p.m.  WELCOME REMARKS AND OPENING KEYNOTE LECTURE
Ballroom 1
6:15 p.m.-6:30 p.m.  Welcome Remarks
6:30 p.m.-7:15 p.m.  Meeting the challenges in ovarian cancer
Joan S. Brugge, Harvard Medical School, Boston, MA

7:30 p.m.-9:30 p.m.  OPENING RECEPTION
King’s Garden 4-5

Monday, October 2

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST AND NETWORKING ROUNDTABLES
Sign up for roundtables at the AACR Registration Desk.
Ballroom 2

8:00 a.m.-10:00 a.m.  PLENARY SESSION 1: DNA DAMAGE AND REPAIR
Ballroom 1
Session Chairs: Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, MA, and Roger A. Greenberg, University of Pennsylvania, Philadelphia, PA
8:00 a.m.-8:20 a.m.  PARP inhibitors as single agents in combinations for ovarian cancer: What lies ahead?
Ursula A. Matulonis
8:20 a.m.-8:40 a.m.  Inhibition of ATR overcomes the PARP inhibitor resistance of BRCA-deficient cancer cells
Lee Zou, MGH Cancer Center/Harvard Medical School, Boston, MA
8:40 a.m.-9:00 a.m.  Mitotic progression connects DNA damage to activation of antitumor immune responses
Roger A. Greenberg
9:00 a.m.-9:10 a.m.  Cyclin E: Targeting cell cycle dependencies in CCNE1-amplified tumors*
Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

*Short talk from proffered abstract
CONFERENCE PROGRAM

9:10 a.m.-9:20 a.m.  Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition*  
Monicka Wielgos-Bonvallet, NYU Langone Medical Center, New York, NY

9:20 a.m.-10:00 a.m.  Plenary Session 1 Discussion

10:00 a.m.-10:30 a.m.  BREAK  
Grand Ballroom 1

10:30 a.m.-12:30 p.m.  PLENARY SESSION 2: METABOLIC CHANGES IN OVARIAN CANCER  
Ballroom 1  
Session Chairs: Ernst R. Lengyel, University of Chicago, Chicago, IL, and Ahmed A. Ahmed, University of Oxford, Oxford, United Kingdom

10:30 a.m.-10:50 a.m.  Title to be announced  
Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, TX

10:50 a.m.-11:10 a.m.  Stromal regulation of metastasis  
Ernst R. Lengyel

11:10 a.m.-11:30 a.m.  Targeting micrometastasis for the treatment of ovarian cancer  
Ahmed A. Ahmed

11:30 a.m.-11:50 a.m.  Kinase-mediated modulation of paclitaxel sensitivity in ovarian cancer  
Zhen Lu, The University of Texas MD Anderson Cancer Center, Houston, TX

11:50 a.m.-12:00 p.m.  Arginine deprivation as a potential targeted therapy for clear cell ovarian carcinoma*  
Jennifer Xiao Ye Ji, University of British Columbia, Vancouver, BC, Canada

12:00 p.m.-12:30 p.m.  Plenary Session 2 Discussion

12:30 p.m.-3:00 p.m.  FREE TIME (LUNCH ON OWN)

3:00 p.m.-5:00 p.m.  PLENARY SESSION 3: TUMOR MICROENVIRONMENT  
Ballroom 1  
Session Chairs: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, TX, and Frances R. Balkwill, Barts Cancer Institute, London, United Kingdom

3:00 p.m.-3:20 p.m.  New directions in tumor microenvironment  
Anil K. Sood

3:20 p.m.-3:40 p.m.  Deconstructing and reconstructing the ovarian cancer microenvironment  
Frances R. Balkwill

3:40 p.m.-4:00 p.m.  Translating preclinical observations into trials addressing changes in the tumor microenvironment  
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX

*Short talk from proffered abstract
4:00 p.m.-4:10 p.m.  Tumor-derived indoleamine 2,3- dioxygenase regulates density of tumor infiltrating CD8+ T cells and myeloid-derived suppressor cells in a murine model of ovarian cancer*
Adaobi E. Amobi, Roswell Park Cancer Institute, Buffalo, NY

4:10 p.m.-4:20 p.m.  Nicotinamide N-methyltransferase metabolically reprograms the stroma to promote ovarian cancer metastasis*
Mark A. Eckert, University of Chicago, Chicago, IL

4:20 p.m.-5:00 p.m.  Plenary Session 3 Discussion

5:00 p.m.-6:00 p.m.  PANEL DISCUSSION: INNOVATIVE TRIAL DESIGN
Ballroom 1
ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs. placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)*
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX

Please refer to Program and Proceedings supplement for more information and additional panelists.

6:00 p.m.-8:30 p.m.  POSTER SESSION A AND RECEPTION
Ballroom 3-4

Tuesday, October 3

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST AND NETWORKING ROUNDTABLES
Sign up for roundtables at the AACR Registration Desk.
Ballroom 2

8:00 a.m.-10:00 a.m.  PLENARY SESSION 4: DRUG RESPONSE AND RESISTANCE TO THERAPY
Ballroom 1
Session Chairs: David D. L. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia, and Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX

8:00 a.m.-8:20 a.m.  Acquired chemotherapy resistance in high-grade serous ovarian cancer patients
David D. L. Bowtell

8:20 a.m.-8:40 a.m.  Systems approach to drug development
Gordon B. Mills

8:40 a.m.-9:00 a.m.  Exploiting synthetic lethality in the treatment of gynecologic cancers
Christopher Lord, Cancer Research UK London Research Institute, London, United Kingdom

*Short talk from proffered abstract
CONFERENCE PROGRAM

9:00 a.m.-9:10 a.m. Combined MEK and BCL-2/XL inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer*
Claudia Iavarone, Ludwig Center at Harvard, Harvard Medical School, Boston, MA

9:10 a.m.-9:20 a.m. Longitudinal sampling of ctDNA reveals actionable mutations to optimize treatment of patients with high-grade serous ovarian cancer*
Kaiyang Zhang, University of Helsinki, Helsinki, Finland

9:20 a.m.-10:00 a.m. Plenary Session 4 Discussion

10:00 a.m.-10:30 a.m. BREAK
Grand Ballroom 1

10:30 a.m.-12:30 p.m. PLENUMAR SESSION 5: PREVENTION AND EARLY DETECTION (Generously supported by Ovarcome)
Ballroom 1
Session Chairs: Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, TX, and Ie-Ming Shih, Johns Hopkins Medical Institutes, Baltimore, MD

10:30 a.m.-10:50 a.m. Early detection of ovarian cancer: An update
Robert C. Bast, Jr.

10:50 a.m.-11:10 a.m. PapGene, PapSEEK, and PapDREAMing for early detection of ovarian cancer
Ie-Ming Shih

11:10 a.m.-11:30 a.m. Physical and in silico methods for improving sensitivity of detection of ctDNA for personalized medicine in high-grade serous ovarian cancer
James D. Brenton, University of Cambridge, Cambridge, United Kingdom

11:30 a.m.-11:40 a.m. Derivation and validation of a serum diagnostic test for ovarian cancer using miRNA-seq*
Kevin M. Elias, Brigham and Women’s Hospital, Boston, MA

11:40 a.m.-11:50 p.m. Breastfeeding protects against epithelial ovarian cancer: Results of the HOPE Study*
Francesmary Modugno, University of Pittsburgh, Pittsburgh, PA

11:50 a.m.-12:30 p.m. Plenary Session 5 Discussion

12:30 p.m.-3:00 p.m. POSTER SESSION B AND LUNCH
Ballroom 3-4

3:00 p.m.-5:00 p.m. PLENUMARY SESSION 6: EXPLOITING VULNERABILITIES IN RARE TUMORS
Ballroom 1
Session Chairs: David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston, TX, and David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

*Short talk from proffered abstract
3:00 p.m.-3:20 p.m.  Progress and future directions in the management of low-grade serous cancer of the ovary  
David M. Gershenson

3:20 p.m.-3:40 p.m.  Granulosa cell and other rare ovarian cancers: Genomic-derived diagnostics and emergent management strategies  
David G. Huntsman

3:40 p.m.-4:00 p.m.  Therapeutic targeting of ARID1A mutation in ovarian cancer  
Rugang Zhang, The Wistar Institute, Philadelphia, PA

4:00 p.m.-4:20 p.m.  Small cell carcinomas of the ovary: Strengths and weaknesses  
Douglas A. Levine, New York University, New York, NY

4:20 p.m.-4:30 p.m.  The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma*  
Darren Ennis, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom

4:30 p.m.-5:00 p.m.  Plenary Session 6 Discussion

5:00 p.m.-6:00 p.m.  PANEL: FUNDING OPPORTUNITIES AND ADVOCACY GROUPS  
Ballroom 1  
Please refer to Program and Proceedings supplement for more information and panelists.

Wednesday, October 4

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST AND NETWORKING ROUNDTABLES  
Sign up for roundtables at the AACR Registration Desk.  
King’s Garden 5

8:00 a.m.-10:00 a.m.  PLENARY SESSION 7: IMMUNOTHERAPY  
Ballroom 1  
Session Chairs: Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY, and David R. Spriggs, Memorial Sloan Kettering Cancer Center, New York, NY

8:00 a.m.-8:20 a.m.  Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy  
Kunle Odunsi

8:20 a.m.-8:40 a.m.  How does the immune system contend with intratumoral heterogeneity in ovarian cancer?  
Brad Nelson, BC Cancer Agency, Vancouver Island, BC, Canada

8:40 a.m.-9:00 a.m.  Translating fundamental immunobiology into adoptive T-cell therapy for ovarian cancer  
Daniel J. Powell, University of Pennsylvania, Philadelphia, PA

*Short talk from proffered abstract
CONFERENCE PROGRAM

9:00 a.m.-9:20 a.m.  Strategies for glycosylation-based immunotargeting of MUC16
David R. Spriggs

9:20 a.m.-9:30 a.m.  Epigenetic reprogramming promotes an immunogenic ovarian tumor
microenvironment and synergizes with adoptive transfer of engineered T cells
expressing NY-ESO-1 specific T-cell receptors*
Li Shen, Roswell Park Cancer Institute, Buffalo, NY

9:30 a.m.-10:00 a.m.  Plenary Session 7 Discussion

10:00 a.m.-10:15 a.m.  BREAK
Grand Ballroom 1

10:15 a.m.-12:15 p.m.  PLENARY SESSION 8: GENETICS AND MOLECULAR DRIVERS
Ballroom 1
Session Chairs: Ronny I. Drapkin, University of Pennsylvania, Philadelphia, PA,
and Robert K. Rottapel, Princess Margaret Cancer Centre, Toronto, ON, Canada

10:15 a.m.-10:35 a.m.  Replication road blocks in Cyclin E-amplified ovarian cancers
Ronny I. Drapkin

10:35 a.m.-10:55 a.m.  Functional genetic architecture of serous ovarian cancer
Robert K. Rottapel

10:55 a.m.-11:15 a.m.  Title to be announced
Andy Futreal, The University of Texas MD Anderson Cancer Center, Houston, TX

11:15 a.m.-11:25 a.m.  TERT is frequently mutated in adult-type granulosa cell tumors of the ovary
compared to other malignant sex cord-stromal tumors*
Jessica A. Pilsworth, University of British Columbia, Vancouver, BC, Canada

11:25 a.m.-11:45 a.m.  CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to
generate improved murine models of ovarian high-grade serous carcinoma*
Josephine Walton, The University of Glasgow, Glasgow, United Kingdom

11:45 a.m.-12:15 p.m.  Plenary Session 8 Discussion

12:15 p.m.  DEPARTURE

*Short talk from proffered abstract